Berkeley Lights to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Berkeley Lights (Nasdaq: BLI) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 11, 2022, at 12:45 p.m. Pacific Time. A live and archived webcast will be available on their Investors section of the website.

Berkeley Lights is at the forefront of digital cell biology, offering a platform that enhances the development of biotherapeutics through advanced automation and software. Their proprietary technology enables comprehensive analysis of single cells, supporting efficient commercialization of cell-based products.

EMERYVILLE, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the Company will be participating virtually in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Berkeley Lights management is scheduled to present on Tuesday, January 11 at 12:45 p.m. Pacific Time / 3:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at www.berkeleylights.com.

About Berkeley Lights

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company’s growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.

Media Contacts
media@berkeleylights.com

Investor Contact
IR@berkeleylights.com

FAQ

When will Berkeley Lights present at the J.P. Morgan Healthcare Conference?

Berkeley Lights is scheduled to present on January 11, 2022, at 12:45 p.m. Pacific Time.

How can I access Berkeley Lights' presentation at the conference?

The presentation can be accessed via a live and archived webcast on the 'Investors' section of the Berkeley Lights website.

What does Berkeley Lights specialize in?

Berkeley Lights specializes in digital cell biology, focusing on the development and commercialization of biotherapeutics and cell-based products.

What is the significance of the Berkeley Lights Platform?

The Berkeley Lights Platform allows for the rapid characterization of single cells, supporting the efficient development of biotherapeutics.

What risks are associated with Berkeley Lights' forward-looking statements?

Forward-looking statements from Berkeley Lights involve risks and uncertainties that may significantly affect actual results.